Alternatives to Rytary If You Can't Fill Your Prescription

Rytary is an important medication for many Parkinson's disease patients, providing smoother motor control through its extended-release carbidopa and levodopa formulation. But when you can't find it at your pharmacy — or the cost makes it inaccessible — it's critical to know what your alternatives are.

This guide covers the most clinically relevant alternatives to Rytary in 2026. Always discuss any medication change with your neurologist before switching — Parkinson's disease medications require careful titration, and an incorrect conversion can temporarily worsen your symptoms.

Important Warning: Do Not Stop Rytary Abruptly

Before reviewing alternatives, this bears repeating: never abruptly discontinue Rytary without medical guidance. Sudden withdrawal can cause a serious condition called neuroleptic malignant syndrome (NMS), characterized by high fever, muscle rigidity, confusion, and rapid heart rate. If you're running low and can't find Rytary, contact your neurologist immediately — don't just stop taking it.

Alternative 1: Crexont (Carbidopa/Levodopa ER Capsules — Approved 2024)

Crexont is the newest extended-release carbidopa-levodopa option, approved by the FDA in 2024. Like Rytary, it uses multi-bead technology with both immediate-release and sustained-release components. A key advantage: Crexont can often be dosed twice daily (vs. Rytary's three to five times daily), which some patients find more convenient.

Conversion from Rytary to Crexont is approximately 1:1 based on the levodopa component, making it the most straightforward switch. However, Crexont is also a brand-name drug requiring prior authorization, and it may not be readily available at all pharmacies. Ask your neurologist if Crexont is an option for you.

Alternative 2: Immediate-Release Carbidopa/Levodopa (Generic Sinemet)

Generic carbidopa/levodopa immediate-release (IR) tablets are widely available and extremely affordable — as low as $8–$17 for 30 tablets at retail, and under $10 with GoodRx or SingleCare coupons. They come in strengths of 10/100 mg, 25/100 mg, and 25/250 mg.

The tradeoff: IR tablets require more frequent dosing (typically 3–4 times daily) and produce more pronounced peaks and troughs in levodopa levels than Rytary's extended-release formulation. Patients who switched to Rytary specifically because of motor fluctuations may notice 'off' periods returning more frequently. This is typically a temporary bridge option while your Rytary supply is secured, not a permanent switch without neurologist guidance.

Important: The dose of IR carbidopa-levodopa is NOT equivalent to Rytary mg-for-mg. Your neurologist will calculate the appropriate conversion dose. Do not attempt to do this yourself.

Alternative 3: Stalevo (Carbidopa/Levodopa/Entacapone)

Stalevo combines carbidopa, levodopa, and entacapone in a single tablet. Entacapone is a COMT (catechol-O-methyltransferase) inhibitor that prevents levodopa from being broken down in the body, extending its duration of action. This makes each dose last longer — which can partially compensate for the loss of extended-release coverage.

Stalevo is available as a generic and typically costs $54–$100 per month with a coupon. It comes in multiple strengths (50, 75, 100, 125, 150, and 200 mg levodopa equivalents). It's a good option for patients who need more 'on' time but can't access Rytary or Crexont. Note: adding entacapone often requires a 10–30% reduction in levodopa dose — your neurologist will guide this.

Alternative 4: Dopamine Agonists (Mirapex, Requip)

Pramipexole (Mirapex) and ropinirole (Requip) are dopamine agonists — they mimic dopamine in the brain rather than replacing it. These are generally used as monotherapy in early-stage Parkinson's or as add-on therapy to levodopa. They will not fully substitute for Rytary in patients with moderate-to-advanced disease who rely on levodopa for motor control.

Generic pramipexole and ropinirole are widely available and affordable. Rotigotine (Neupro) is a dopamine agonist patch that some patients use as an adjunct. These options may help manage some symptoms if levodopa supplies are temporarily disrupted, but should only be added or adjusted under neurologist guidance.

Alternative 5: Duopa (Carbidopa/Levodopa Enteral Suspension)

Duopa is a gel formulation of carbidopa-levodopa delivered directly into the small intestine via a PEG-J tube. It's designed for patients with advanced Parkinson's who have severe motor fluctuations despite optimal oral therapy. It is not a typical 'alternative' to Rytary for most patients — it's a specialized escalation for advanced cases. It's mentioned here for completeness, not as a realistic first-line switch option.

Quick Comparison Table

Crexont: ER capsule | 2x/day | Brand only | ~Rytary pricing | Easy 1:1 conversion from Rytary

Carbidopa/Levodopa IR: IR tablet | 3–4x/day | Generic available | $8–$17 | Requires neurologist conversion

Stalevo: IR + COMT inhibitor | 3–4x/day | Generic available | $54–$100/month | Good for wearing-off

Dopamine agonists: Oral/patch | Varies | Generic available | $15–$40/month | Adjunct only, not full substitute

The Bottom Line

If you can't fill your Rytary prescription, your first call should be to your neurologist's office — not a random alternative. The conversion from Rytary to any other carbidopa-levodopa formulation requires calculating the right dose to maintain your motor control. While you work on finding Rytary (see our guide on how to find Rytary in stock near you), your neurologist can prescribe a bridge therapy to keep your symptoms managed safely.